The effect of changes in thyroxine and thyroid-stimulating hormone levels on the coagulation system

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 12, 2010, Pages 2823-2826

  Debeij, J ^a   Cannegieter, S C ^a   Van Zaane, B ^b,c   Smit, J W A ^a   Corssmit, E P M ^a   Rosendaal, F R ^a   Romijn, J A ^a   Dekkers, O M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; FIBRINOGEN; LEVOTHYROXINE; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROTROPIN; THYROXINE; VON WILLEBRAND FACTOR;

ABLATION THERAPY; ADULT; BLOOD CLOTTING; BLOOD PRESSURE; BONE METABOLISM; CLINICAL ARTICLE; FEMALE; FREE THYROXINE INDEX; GENE EXPRESSION; HEART RATE; HUMAN; LETTER; MALE; PRIORITY JOURNAL; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL;

BLOOD COAGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; THYROID FUNCTION TESTS; THYROID GLAND; THYROTROPIN; THYROXINE;

EID: 78650036163     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.04054.x     Document Type: Letter

References (23)

1. Franchini M. Hemostatic changes in thyroid diseases: haemostasis and thrombosis. Hematology 2006; 11: 203-8.
2. Hofbauer LC, Heufelder AE. Coagulation disorders in thyroid diseases. Eur J Endocrinol 1997; 136: 1-7.
3. Squizzato A, Gerdes VE, Brandjes DP, Buller HR, Stam J. Thyroid diseases and cerebrovascular disease. Stroke 2005; 36: 2302-10.
4. Squizzato A, Romualdi E, Buller HR, Gerdes VE. Clinical review: Thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review. J Clin Endocrinol Metab 2007; 92: 2415-20.
5. Erem C, Kavgaci H, Ersoz HO, Hacihasanoglu A, Ukinc K, Karti SS, Deger O, Telatari M. Blood coagulation and fibrinolytic activity in hypothyroidism. Int J Clin Pract 2003; 57: 78-81.
6. Homoncik M, Gessl A, Ferlitsch A, Jilma B, Vierhapper H. Altered platelet plug formation in hyperthyroidism and hypothyroidism. J Clin Endocrinol Metab 2007; 92: 3006-12.
7. Abe E, Marians RC, Yu W, Wu XB, Ando T, Li Y, Iqbal J, Eldeiry L, Rajendren G, Blair HC, Davies TF, Zaidi M. TSH is a negative regulator of skeletal remodeling. Cell 2003; 115: 151-62.
8. De Lloyd A, Bursell J, Gregory JW, Rees DA, Ludgate M. TSH receptor activation and body composition. J Endocrinol 2010; 204: 13-20.
9. Mazziotti G, Sorvillo F, Piscopo M, Cioffi M, Pilla P, Biondi B, Iorio S, Giustina A, Amato G, Carella C. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma. J Bone Miner Res 2005; 20: 480-6.
10. Heemstra KA, Burggraaf J, Van Der Klaauw AA, Romijn JA, Smit JW, Corssmit EP. Short-term overt hypothyroidism induces sympathovagal imbalance in thyroidectomized differentiated thyroid carcinoma patients. Clin Endocrinol (Oxf) 2010; 72: 417-21.
11. Heemstra KA, Hamdy NA, Romijn JA, Smit JW. The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. Thyroid 2006; 16: 583-91.
12. Pacini F, Castagna MG. Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer. Best Pract Res Clin Endocrinol Metab 2008; 22: 1009-21.
13. Erem C, Ersoz HO, Karti SS, Ukinc K, Hacihasanoglu A, Deger O, Telatar M. Blood coagulation and fibrinolysis in patients with hyperthyroidism. J Endocrinol Invest 2002; 25: 345-50.
14. Gullu S, Sav H, Kamel N. Effects of levothyroxine treatment on biochemical and hemostasis parameters in patients with hypothyroidism. Eur J Endocrinol 2005; 152: 355-61.
15. Michiels JJ, Schroyens W, Berneman Z, Van Der Planken M. Acquired von Willebrand syndrome type 1 in hypothyroidism: reversal after treatment with thyroxine. Clin Appl Thromb Hemost 2001; 7: 113-15.
16. Squizzato A, Gerdes VE. Thyroid disease and haemostasis - a relationship with clinical implications? Thromb Haemost 2008; 100: 727-8.
17. Shih CH, Chen SL, Yen CC, Huang YH, Chen CD, Lee YS, Lin KH. Thyroid hormone receptor-dependent transcriptional regulation of fibrinogen and coagulation proteins. Endocrinology 2004; 145: 2804-14.
18. Frigo A, Dardano A, Danese E, Davi MV, Moghetti P, Colato C, Francia G, Bernardi F, Traino C, Monzani F, Ferdeghini M. Chromosome translocation frequency after radioiodine thyroid remnant ablation: a comparison between recombinant human thyrotropin stimulation and prolonged levothyroxine withdrawal. J Clin Endocrinol Metab 2009; 94: 3472-6.
19. Schobersberger W, Fries D, Mittermayr M, Innerhofer P, Sumann G, Schobersberger B, Klingler A, Stollnberger V, Fischbach U, Gunga HC. Changes of biochemical markers and functional tests for clot formation during long-haul flights. Thromb Res 2002; 108: 19-24.
20. Schreijer AJ, Cannegieter SC, Meijers JC, Middeldorp S, Buller HR, Rosendaal FR. Activation of coagulation system during air travel: a crossover study. Lancet 2006; 9513: 832-8.
21. Stricker H, Colucci G, Alberio L, Mombelli G. Variation in coagulation inhibitors during prolonged sitting: possible pathogenetic mechanisms for travel-associated thrombosis. J Thromb Haemost 2006; 4: 900-2.
22. Fender D, Harper WM, Thompson JR, Gregg PJ. Mortality and fatal pulmonary embolism after primary total hip replacement. Results from a regional hip register. J Bone Joint Surg Br 1997; 79: 896-9.
23. Van Zaane B, Squizzato A, Huijgen R, Van Zanten AP, Fliers E, Cannegieter SC, Buller HR, Gerdes VE, Brandjes DP. Increasing levels of free thyroxine as a risk factor for a first venous thrombosis: a case-control study. Blood 2010; 115: 4344-9.